Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2013-01-08 Regulatory Filings
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
Press Release: 4SC obtains key patent for anti-cancer compound resminostat in Europe
Regulatory Filings Classification · 100% confidence The document is explicitly titled 'Press Release' and announces a specific corporate event: '4SC obtains key patent for anti-cancer compound resminostat in Europe'. It details the patent grant notice from the European Patent Office and discusses the implications for the company's lead compound. This type of announcement, which is a specific, non-periodic corporate update (not a full financial report like 10-K or IR, nor a management/board change), fits best under the general 'Regulatory Filings' category (RNS) as it is a material, non-scheduled disclosure disseminated via a news service (DGAP). It is not an Earnings Release (ER), a Capital Update (CAP), or a Director's Dealing (DIRS). Since it is a specific news item disseminated broadly, RNS is the most appropriate general regulatory filing code.
2013-01-08 English
Konzernabschluss zum Geschäftsjahr vom 01.01.2011 bis zum 31.12.2011
Audit Report / Information Classification · 95% confidence The document is titled 'Bericht des Aufsichtsrats 2011' (Report of the Supervisory Board 2011) for 4SC AG. It details the activities, meetings, committee structures, and governance oversight performed by the Supervisory Board during the 2011 fiscal year. This type of report is a standard component of a company's annual reporting package, specifically focusing on corporate governance and board oversight. Since it is a standalone section of the annual reporting cycle detailing governance and board activities, it is classified as Governance Information. FY 2011
2012-12-20 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2010 bis zum 31.12.2010
Audit Report / Information Classification · 95% confidence The document is a 'Bericht des Aufsichtsrats' (Report of the Supervisory Board) for 4SC AG for the fiscal year 2010. It details the board's activities, committee meetings, and oversight of the management. While it is part of the annual reporting package, it is a specific component (Supervisory Board Report) rather than the full 10-K or a standalone audit report. In the context of corporate governance and annual reporting, this document is classified as Governance Information (CGR) as it focuses on board structure, internal rules, and oversight activities. FY 2010
2012-12-18 German
Press Release: 4SC Discovery and BioNTech announce exclusive research and license agreement for 4SC's TLR agonists for cancer immunotherapy
Regulatory Filings Classification · 100% confidence The document is a 'Press Release' dated December 17, 2012, announcing an 'exclusive research and license agreement' between 4SC Discovery and BioNTech regarding TLR agonists for cancer immunotherapy. It details upfront payments, licensing rights, milestone payments, and royalties. This type of announcement, detailing a significant business development, partnership, or licensing deal, falls under the category of corporate news that is often released via regulatory channels but specifically describes a strategic transaction. Since it is not a formal financial report (like 10-K or IR), a management discussion (MDA), or a specific insider transaction (DIRS), the most appropriate classification for a significant, non-standard corporate announcement that is disseminated broadly is 'Regulatory Filings' (RNS), which serves as a general category for corporate news releases that don't fit elsewhere, especially when disseminated through services like DGAP.
2012-12-17 English
Press Release: 4SC announces positive interim results from clinical Phase I/II trial with anti-cancer compound resminostat in colorectal cancer
Regulatory Filings Classification · 90% confidence The document is a 'Press Release' announcing 'positive interim results from clinical Phase I/II trial with anti-cancer compound resminostat in colorectal cancer'. It details clinical trial progress, safety, tolerability, and future plans (Phase II start). This content is characteristic of an announcement regarding ongoing clinical development and trial outcomes, which is typically released to investors and the public. It is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), or a formal dividend notice. Since it is a press release detailing specific operational/clinical news, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially an 'Earnings Release' (ER) if it were tied to a financial period, but here it is purely clinical news. Given the options, RNS serves as the best general category for non-standard, yet important, corporate news releases that aren't explicitly covered by other codes like DIV, CAP, or ER (which usually focuses on financial performance metrics). However, since it is a detailed announcement of clinical trial results, it is a significant piece of corporate information. In many databases, detailed clinical updates are often grouped under general regulatory announcements or investor relations material. Given the available codes, RNS (Regulatory Filings/Miscellaneous) is the most appropriate fallback for a detailed clinical press release that isn't a financial report or a specific management change.
2012-12-12 English
Press Release: 4SC reports positive data from clinical Phase I trial with 4SC-205 in cancer patients and initiates study amendment
Regulatory Filings Classification · 95% confidence The document is titled "Press Release" and announces positive data from a clinical Phase I trial (AEGIS) for a drug candidate (4SC-205) and an initiation of a study amendment. It details clinical results (safety, MTD, PK profile) and provides background on the drug and the company (4SC AG). This type of announcement, focusing on clinical trial progress and study amendments, is a standard form of corporate news release related to R&D pipeline updates. It is not a formal regulatory filing like a 10-K, a comprehensive quarterly report (IR), an earnings release (ER), or a specific shareholder/governance document. Since it is a general corporate announcement disseminated via a service (DGAP) that handles press releases and corporate news, and it doesn't fit the highly specific categories like ER, IR, or CAP, the most appropriate classification is the general regulatory/corporate announcement fallback, RNS (Regulatory Filings), as it is a formal news release about company operations/pipeline.
2012-12-05 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.